MX2021013971A - Regimen de dosificacion de eltrombopag. - Google Patents
Regimen de dosificacion de eltrombopag.Info
- Publication number
- MX2021013971A MX2021013971A MX2021013971A MX2021013971A MX2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A
- Authority
- MX
- Mexico
- Prior art keywords
- eltrombopag
- dosage regime
- itp
- administering
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/032171 WO2020231407A1 (en) | 2019-05-14 | 2019-05-14 | Eltrombopag dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013971A true MX2021013971A (es) | 2022-04-01 |
Family
ID=67211802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013971A MX2021013971A (es) | 2019-05-14 | 2019-05-14 | Regimen de dosificacion de eltrombopag. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220313663A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3968984A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022537883A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035036A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019445762A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3140137A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288078A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013971A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020231407A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201406373A (zh) * | 2012-06-29 | 2014-02-16 | Shionogi & Co | 含有具有血栓形成素受體促效作用之化合物之醫藥組合物 |
-
2019
- 2019-05-14 EP EP19737274.1A patent/EP3968984A1/en not_active Withdrawn
- 2019-05-14 CA CA3140137A patent/CA3140137A1/en active Pending
- 2019-05-14 JP JP2021568408A patent/JP2022537883A/ja not_active Withdrawn
- 2019-05-14 MX MX2021013971A patent/MX2021013971A/es unknown
- 2019-05-14 IL IL288078A patent/IL288078A/en unknown
- 2019-05-14 WO PCT/US2019/032171 patent/WO2020231407A1/en not_active Ceased
- 2019-05-14 AU AU2019445762A patent/AU2019445762A1/en not_active Abandoned
- 2019-05-14 KR KR1020217040929A patent/KR20220035036A/ko not_active Ceased
- 2019-05-14 US US17/611,012 patent/US20220313663A1/en not_active Abandoned
-
2023
- 2023-09-27 JP JP2023166306A patent/JP2023182667A/ja active Pending
- 2023-11-27 AU AU2023274065A patent/AU2023274065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023182667A (ja) | 2023-12-26 |
| AU2019445762A1 (en) | 2021-12-09 |
| AU2023274065A1 (en) | 2023-12-14 |
| JP2022537883A (ja) | 2022-08-31 |
| US20220313663A1 (en) | 2022-10-06 |
| IL288078A (en) | 2025-01-01 |
| CA3140137A1 (en) | 2020-11-19 |
| WO2020231407A1 (en) | 2020-11-19 |
| KR20220035036A (ko) | 2022-03-21 |
| EP3968984A1 (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
| EA201791576A1 (ru) | Ингибитор jak | |
| MX2019001814A (es) | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. | |
| MX2017003414A (es) | Terapia de combinacion para alzheimer que usa anticuerpos abeta anti-n3pglu + un inhibidor de bace. | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2022005522A (es) | Formas de sal de un receptor de componente c5a de complemento. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| MX2019014291A (es) | Metodo de tratamiento. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. |